Neulasta Biosimilar Approval ‘Within Next Several Months,’ Apotex Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Apotex seeks expedited review of district court order that it must wait until approval to give Amgen 180-day marketing notice.